

BORDEAUX, FRANCE / AUGUST 12<sup>TH</sup> 2024

## **RebrAln Achieves Second FDA 510(k) Clearance, Enhancing Precision in Neurosurgical Targeting with Advanced AI Technology**

### **Co-Founders to Showcase Breakthrough VIM Targeting Techniques at the WSSFN Congress, Highlighting Innovations in Deep Brain Stimulation and Lesioning Procedures**

**RebrAln receives second FDA 510k clearance to optimize targeting of stereotactic and functional neurosurgery for both Deep Brain Stimulation and lesioning techniques (MRgFUS and Radiosurgery); Co-founders presenting VIM Targeting at the congress WSSFN, World Society for Stereotactic and Functional Neurosurgery**

- RebrAln's OptimMRI software is now FDA 510k-cleared with a new machine learning model for assisting in targeting a new brain's region of interest, the infero-lateral part of the VIM, for lesioning techniques such as MRgFUS and Radiosurgery. This new software version already contains FDA cleared machine learning models such as the STN and VIM regions of interest, to help in targeting of Deep Brain Stimulation.
- RebrAln's co-founders, Pr. Emmanuel Cuny, MD and Pr. Nejib Zemzemi, PhD will be presenting on VIM targeting at the World Society for Stereotactic and Functional Neurosurgery (WSSFN) biennial meeting in Chicago, IL on September 5th, 2024.

RebrAln, a commercial-stage precision neurosurgery platform company recently received its second FDA 510k clearance in the last year to expand the software's performance by including the inferolateral part of the VIM. RebrAln's software as medical device (SaMD) aims to revolutionize neurosurgical target planning by coupling advanced AI algorithms trained on clinical data with MRI sequences to provide neurosurgeons with the most optimal targets for lesioning and electrode placement.

David Caumartin, CEO of RebrAln, said "Our extension to US customers to better plan targets for lesioning is a significant step in RebrAln's growth and strategic transformation: indeed the US market is the largest opportunity to enable personalized targeting

#### **About RebrAln**

RebrAln is a French-based company that enables precise targeting for DBS and lesioning treatments for patients suffering from severe Parkinson's or essential tremor disease. Its SaaS solution helps neurosurgeons to precisely identify the target area for surgical intervention. Its novel approach uses machine learning of clinical patient data to predict optimal treatment zone in each patient's brain.

#### **Contact**

##### **US Customers**

Robert Law  
US Business Development  
Leader  
+1 (734)904-1997  
robert.law@rebrain.eu

##### **OUS Customers**

David Caumartin  
CEO  
david.caumartin@rebrain.eu



Pr. Emmanuel Cuny, MD and Pr. Nejib Zemzemi, PhD and David Caumartin, CEO

for neurological disorders such as Essential Tremor disease. The ability to offer AI clinical targeting to neurosurgical suites will open many collaborations nationwide, which today are treated with DBS and MR guided focused ultrasound. Since our recent discussions in US congresses, it was necessary for us to offer neurosurgeons with a complete service.”

Pr. Emmanuel Cuny, MD and Pr. Nejib Zemzemi, PhD will be presenting on “VIM Lesions In Radiosurgery And Focused Ultrasound: Assessment of the accuracy of two targeting models based on machine learning.”

Targeting the ventro-intermediate nucleus (VIM) remains a challenge for lesioning techniques such as radiosurgery (RS) or MR-guided focused ultrasound (MRgFUS). Are the lesioning targets equivalent to those used in DBS?

To evaluate the ideal target locations, we examined the localization of lesions in the ventro-intermediate nucleus (VIM) in successfully treated tremor patients (considered our gold standard) and compared it with predictions generated by machine learning.

- Where: **The Swissotel Chicago – St. Gallen 1+2**
- When: **Thursday, September 5, 2024 at 3:30PM**

**To learn more, please visit us at Booth #9 during the WSSFN meeting, check out our website ([rebrain.eu](https://rebrain.eu)), or contact us directly.**

#### About the World Society for Stereotactic and Functional Neurosurgery

Since 1961, the WSSFN has been regularly held and continues to be a leading neurosurgery conference. At the biennial meetings, the top leaders in the field present the most recent innovations in clinical and basic research, as well as new and effective ways to provide material support.

#### About RebrAIn

RebrAIn is a French-based company that enables precise targeting for DBS and lesioning treatments for patients suffering from severe Parkinson's or essential tremor disease. Its SaaS solution helps neurosurgeons to precisely identify the target area for surgical intervention. Its novel approach uses machine learning of clinical patient data to predict optimal treatment zone in each patient's brain.

#### Contact

##### US Customers

Robert Law  
US Business Development  
Leader  
+1 (734)904-1997  
[robert.law@rebrain.eu](mailto:robert.law@rebrain.eu)

##### OUS Customers

David Caumartin  
CEO  
[david.caumartin@rebrain.eu](mailto:david.caumartin@rebrain.eu)